8-K: Chimerix Receives Nasdaq Non-Compliance Notice Due to Low Share Price

Chimerix, Inc. has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement, as its stock price has remained below $1.00 for 30 consecutive business days.

Summary

• Chimerix, Inc. received a notice from Nasdaq on June 27, 2024, stating that the company is not compliant with the minimum bid price rule.
• The company's stock price has been below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).
• This notification does not immediately affect the listing or trading of Chimerix's stock on the Nasdaq Global Market.
• Chimerix has 180 calendar days, until December 24, 2024, to regain compliance by having its stock price meet or exceed $1.00 for at least ten consecutive business days.
• If the company fails to regain compliance by December 24, 2024, it may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market.
• To qualify for the additional period, Chimerix would need to meet the continued listing requirements for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, except for the bid price requirement.
• The company intends to monitor its stock price and consider options to regain compliance, but there is no guarantee it will be successful.
• Failure to regain compliance could result in the delisting of Chimerix's common stock.

Sentiment

Score: 3

Explanation: The document indicates a negative development with the company's stock price falling below the Nasdaq minimum bid price, creating uncertainty about the company's future listing status.

Positives

• The notification of noncompliance has no immediate effect on the listing or trading of the company's common stock.
• Chimerix has 180 calendar days to regain compliance with the minimum bid price requirement.
• The company may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market.

Negatives

• Chimerix's stock price has been below $1.00 for 30 consecutive business days, triggering the non-compliance notice.
• There is no assurance that the company will be able to regain compliance with Nasdaq's listing rule.
• Failure to regain compliance could result in the delisting of the company's common stock.

Risks

• The company faces the risk of delisting if it cannot raise its stock price above $1.00 within the given timeframes.
• There is uncertainty regarding the company's ability to regain compliance with Nasdaq's listing requirements.
• The company's stock price may be negatively impacted by the non-compliance notice.

Future Outlook

The company intends to actively monitor the bid price of its common stock and will consider available options to regain compliance with the listing requirements, but there is no assurance of success.

Management Comments

• The company intends to actively monitor the bid price of its common stock and will consider available options to regain compliance with the listing requirements.

Industry Context

This announcement is not uncommon for companies that have experienced a significant drop in their stock price, and it highlights the challenges faced by companies in maintaining listing requirements on major exchanges.

Comparison to Industry Standards

• Many biotech companies, especially those in the development stage, face challenges in maintaining a minimum share price.
• Companies like Agenus and Cassava Sciences have also faced similar delisting warnings in the past.
• The Nasdaq minimum bid price rule is a common hurdle for smaller cap companies, and Chimerix's situation is not unique in the industry.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment due to the non-compliance notice.
• Employees may face uncertainty about the company's future.
• Creditors may be concerned about the company's financial stability.

Next Steps

• Chimerix will actively monitor its stock price.
• Chimerix will consider available options to regain compliance with Nasdaq listing requirements.
• Chimerix may need to transfer to the Nasdaq Capital Market if it fails to regain compliance by December 24, 2024.

Key Dates

Keywords

Nasdaq, delisting, compliance, minimum bid price, stock price, Chimerix, listing rule